Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma

被引：0
|
作者：
Gurnell, M. [1 ]
Domingo, C. [2 ,3 ]
Rabe, K. F. [4 ,5 ]
Menzies-Gow, A. [6 ]
Price, D. [7 ]
Brusselle, G. [8 ]
Wechsler, M. E. [9 ]
Xia, C. [10 ]
Pandit-Abid, N. [11 ]
Gall, R. [10 ]
Jacob-Nara, J. A. [11 ]
Rowe, P. J. [11 ]
Deniz, Y. [10 ]
Siddiqui, S. [10 ]
机构：
[1] Univ Cambridge, Wellcome MRC Inst Metab Sci, Cambridge, England
[2] Corp Sanitaria Parc Tauli, Sabadell, Spain
[3] Autonomous Univ Barcelona, Barcelona, Spain
[4] LungenClin Grosshansdorf, Airway Res Ctr North ARCN, Grosshansdorf, Germany
[5] German Ctr Lung Res DZL, Grosshansdorf, Germany
[6] Royal Brompton & Harefield Hosp, London, England
[7] Observat & Pragmat Res Inst, Midview City, Singapore
[8] Univ Ghent, Ghent, Belgium
[9] Natl Jewish Hlth, Denver, CO USA
[10] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[11] Sanofi, Bridgewater, NJ USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2022年 / 60卷
关键词：
Asthma; Adults; Treatments;
D O I：
10.1183/13993003.congress-2022.3620
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
3620
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Persistent Reductions in OCS Use in Patients with Severe, OCS-Dependent Asthma Treated with Dupilumab: LIBERTY ASTHMA TRAVERSE Study
    Gurnell, M.
    Ribas, C. Domingo
    Rabe, K. F.
    Menzies-Gow, A.
    Price, D.
    Brusselle, G.
    Wechsler, M. E.
    Xia, C.
    Djandji, M.
    Gall, R.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y.
    Siddiqui, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [2] Dupilumab improved lung function parameters in OCS-Dependent asthma patients: TRAVERSE
    Castro, M.
    Papi, A.
    Corren, J.
    Pavord, I
    Tohda, Y.
    Mao, X.
    Ortiz, B.
    Djandji, M.
    Ruddy, M.
    Laws, E.
    Mannent, L.
    Amin, N.
    Gall, R.
    Jacob-Nara, J.
    Deniz, Y.
    Rowe, P.
    Lederer, D.
    Hardin, M.
    RESPIROLOGY, 2022, 27 : 93 - 94
  • [3] Persistent reductions in OCS use in patients with severe, OCS-dependent asthma treated with dupilumab: LIBERTY -ASTHMA TRAVERSE study
    Gurnell, M.
    Domingo, C.
    Rabe, K. F.
    Menzies-Gow, A.
    Price, D.
    Brusselle, G.
    Wechsler, M. E.
    Xia, C.
    Djandji, M.
    Gall, R.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y.
    Siddiqui, S.
    ALLERGOLOGIE, 2022, 45 (08) : 610 - 611
  • [4] Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients
    Sher, Lawrence
    Wechsler, Michael E.
    Rabe, Klaus F.
    Maspero, Jorge F.
    Daizadeh, Nadia
    Mao, Xuezhou
    Ortiz, Benjamin
    Mannent, Leda P.
    Laws, Elizabeth
    Ruddy, Marcella
    Pandit-Abid, Nami
    Lederer, David J.
    Hardin, Megan
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [5] Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma: LIBERTY ASTHMA TRAVERSE study
    Park, Hye Yun
    Gurnell, Mark
    Domingo, Christian
    Rabe, Klaus F.
    Menzies-Gow, Andrew
    Price, David
    Brusselle, Guy
    Wechsler, Michael E.
    Xia, Changming
    Pandit-Abid, Nami
    Gall, Rebecca
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    Siddiqui, Shahid
    RESPIROLOGY, 2023, 28 : 20 - 22
  • [6] Dupilumab reduces oral corticosteroid (OCS) use and severe exacerbations, and improves FEV1 in OCS-dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps
    Rabe, K. F.
    Castro, M.
    Nair, P.
    Rice, M. S.
    Rowe, P.
    Deniz, Y.
    Staudinger, H.
    Graham, N. M. H.
    Amin, N.
    Teper, A.
    ALLERGY, 2019, 74 : 35 - 35
  • [7] Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma
    Domingo, Christian
    Hanania, Nicola
    Canonica, Giorgio
    Halpin, David
    Lugogo, Njira
    Rhee, Chin Kook
    Altincatal, Arman
    Pandit-Abid, Nami
    Nash, Scott
    Deniz, Yamo
    Rowe, Paul
    Sacks, Harry
    Jacob-Nara, Juby
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB102 - AB102
  • [8] Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma
    Domingo, C.
    Lommatzsch, M.
    Hanania, N.
    Canonica, G.
    Halpin, D.
    Lugogo, N.
    Rhee, C.
    Altincatal, A.
    Pandit-Abid, N.
    Nash, S.
    Deniz, Y.
    Rowe, P.
    Sacks, H.
    Jacob-Nara, J.
    PNEUMOLOGIE, 2024, 78 : S6 - S6
  • [9] Eosinophilic refractory inflammation in OCS-dependent severe asthma
    Carriero, Vitina
    Bertolini, Francesca
    Arrigo, Elisa
    Ricciardolo, Fabio Luigi Massimo
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [10] Dupilumab Reduced Oral Corticosteroid (OCS) Use in Patients with OCS-Dependent, Severe Asthma Consistently Across Baseline Demographic Characteristics in the Phase 3 LIBERTY ASTHMA VENTURE Study
    Maspero, J. F.
    Ford, L. B.
    Daizadeh, N.
    Pandit-Abid, N.
    Ortiz, B.
    Rowe, P.
    Deniz, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345